repatha prolia futur growth driver
maintain hold rate maintain tp
tp base forward price-to-earnings multipl
adjust ep provid
upsid potenti
estim base follow factor double-
digit volum growth new recent launch product
develop pipelin recent collabor
strong growth repatha prolia
revenu increas y/i
quarter due strong volum growth new recent
launch product outpac declin matur
product sale increas y/i
quarter revenu increas
compar due mileston payment
receiv relat aimovig partnership novarti
top two sell product enbrel neulasta
suffer y/i declin enbrel treat arthriti
declin sale face marketplac competit
caus lower price product
total revenu neulasta declin
quarter due increas competit lower sell
price neulasta expect face biosimilar competit
 come year enbrel neulasta repres
nearli total sale quarter
compani name inc tickeramgnstock ratingholdunchangedindustri viewoverweightpositivepric dec week week volum volum p/en/adilut ep margin margin ttm per share growth profit ttm ttm incom ttm earn growth inc decemb
incom statement
non-
per share item
product perform develop
valuat consensu perform
sever newer product show high
level growth repatha grew
quarter due higher unit demand repatha
approv sale china drive growth
futur
prolia best gross product sale grew
quarter due higher unit
xgeva sale grew quarter
due higher unit sale xgeva approv use
patient multipl myeloma earli
help product take market share
kyproli sale increas
quarter due growth intern sale
number new patient increas kyproli approv
 food drug administr per week
dose octob
agreement market biosimilar
abbvi humira world top sell drug
brought biosimilar amgevita market eu
octob wait sell
biosimilar pay royalti
right amgevita
look fundament strong expect
growth revenu growth revenu
sinc stock volatil quarter
price-to-earnings nearli previou quarter
therefor maintain tp
stock price histori date high obsolet date obsolet move move share statist averag volum averag volum share held held share short short share short prior month error dividend split forward annual dividend forward annual dividend trail annual dividend trail annual dividend year averag dividend pay-out dividend date dec ex-dividend date feb last split factor new per last split date inform amgen inc decemb
incom statement
non-
per share item
product perform develop
valuat consensu perform
non- reconcili refer page
incom statement item total gross research sale gener oper total oper oper interest incom incom provis incom net incom avail common weight averag share annual actual annual actual quarterli inc decemb
cash short-term total current total current net properti plant intang long-term total non-curr total short-term account accru current total current long-term defer tax long-term total non-curr total common retain accumul comprehens total stockhold total liabil stockhold balanc sheet itemsactu annual actual quarterli inc decemb
provid oper activ decreas period
compar net cash decreas due higher cash tax result
first instal payment repatri tax aris tax act net reduc payment
on-going incom tax liabil time payment vendor substanti off-set higher
sale incent allow paid custom
provid invest activ period compar
cash use invest activ increas due activ relat
market secur
use financ activ period compar
due repurchas common stock payment dividend repay debt
depreci investment/asset impair defer incom stock base chang work account account incom tax work non-cash net cash provid oper invest properti plant properti plant equip acquisit purchas sales/matur purchas invest net cash use invest debt debt common stock common stock dividend financ net cash provid use financ net chang begin end inc decemb
deliv strong result due strong double-digit volume-
driven growth new recent launch product
increas
compar
total revenu increas compar
total product revenu increas
compar due higher unit demand
partial off-set declin net sell price total revenu
increas compar
due higher mileston payment
increas
compar
gaap sale increas compar
gaap sale total revenu increas
compar increas due
higher manufactur cost higher acquisition-rel amort
intang asset increas partial off-set lower royalti cost
favor comparison hurrican maria-rel charg
non-gaap sale increas compar
non-gaap cog product sale increas
compar
sg expens increas compar
sg expens total revenu
increas compar
increas due invest product launch market product
non-gaap sg expens increas
compar non-gaap sg expens
product sale increas compar
 expens increas compar
 expens total revenu
compar increas due
increas later-stag clinic program discoveri
research translat scienc off-set partial
decreas marketed-product support
non-gaap expens increas
compar non-gaap expens
product sale compar
oper expens increas compar
increas due higher impairment-rel charg
associ intang asset acquir busi combin
oper expens increas
compar non-gaap oper expens increas
compar
oper incom decreas compar
non-gaap oper incom declin
compar
interest expens increas compar
due impact rise interest rate variable-r
interest incom net decreas
compar decreas due higher
invest loss reduc return result liquid
portion portfolio
tax rate decreas compar
non-gaap tax rate decreas compar
decreas tax rate due impact
gaap net incom decreas compar
non-gaap net incom flat
compar
decreas
compar
decreas
compar
gaap ep increas compar
non-gaap ep increas compar
gener free cash flow compar
decreas due time tax payment
amgen dividend per share declar juli
paid sept stockhold record aug
quarter repurchas share common stock
total cost end quarter remain
stock repurchas author
period total revenu increas
compar period total
product sale increas compar
period total revenu increas
compar
period cost sale decreas
compar period cost sale
total revenu declin compar
decreas cog due lower royalti cost decreas
acquisition-rel amort intang asset
period expens increas
compar period expens
total revenu compar
increas due increas later-stag clinic program
discoveri research translat scienc
off-set partial decreas marketed-product support
gaap ep increas
compar
increas
compar
period sg expens increas
compar period sg
expens total revenu increas compar
period oper expens declin
compar period
oper expens increas compar
period oper incom increas
compar
period interest expens increas
compar period tax rate
compar
period net incom increas
compar period ep
increas compar
increas
compar
market six therapeut area cardiovascular neurosci
oncology/hematolog inflamm nephrolog bone health
princip product neulasta enbrel sensipar/mimpara prolia
aranesp xgeva epogen also market number product
parsabiv imlyg corlanor aimovig kanjinti
total revenu prolia
increas
compar
total product sale increas compar
due higher unit demand period
total product sale increas compar
total product sale decreas
compar total product sale rest
world increas compar
total revenu prolia increas
compar period total
revenu increas compar
increas due higher unit demand
total revenu increas
compar total revenu rest
world increas compar
total revenu xgeva increas
compar period total
revenu increas compar
increas due higher unit demand
total revenu xgeva
increas
compar
total revenu increas
compar total revenu rest world
increas compar
total revenu kyproli increas
compar period total
revenu increas compar
total revenu increas
compar total revenu rest world
increas compar
total revenu
kyproli increas
compar
total revenu
repatha increas
compar
total revenu parsabiv compar
period total revenu
total revenu total revenu
rest world
total revenu repatha increas
compar period total
revenu increas compar
total revenu increas
compar total revenu rest world
compar
total revenu sensipar decreas
compar due lower unit demand
due continu adopt parsabiv
total revenu
sensipar decreas
compar
due lower
unit demand
due continu adopt
parsabiv
period total revenu increas
compar due increas net sell
total revenu declin
compar total revenu rest world
decreas compar
total revenu nplate increas
compar period total
revenu increas compar
total revenu increas
compar total revenu rest world
increas compar
total revenu nplate
increas
compar
total revenu blyncyto increas
compar period total
revenu increas compar
total revenu decreas
compar total revenu rest world
increas compar
total revenu vectibix increas
compar period total
revenu increas compar
total revenu
aranesp decreas
compar
total revenu increas
compar total revenu rest world
increas compar
total revenu epogen
decreas
compar
total revenu aranesp decreas
compar period total
revenu declin compar
declin due impact competit unit demand
total revenu declin
compar total revenu rest world
declin compar
total revenu epogen decreas
compar decreas epogen sale
due decreas net sell price due contractu term negoti
davita inc
period total revenu declin
compar decreas epogen sale
due decreas net sell price lower unit demand
total revenu
decreas
compar
total revenu enbrel
decreas
compar
total revenu aimovig
period
total revenu decreas
compar period total
revenu declin compar
total revenu declin
compar total revenu rest world
decreas compar
total revenu enbrel decreas
compar period total
revenu declin compar
declin due lower unit demand lower net sell
total revenu declin
compar total revenu rest world
declin compar
total revenu neulasta decreas
compar period total
revenu decreas compar
total revenu decreas
compar total revenu rest world
decreas compar
follow signific develop
once-weekli dose option combin dexamethason
approv patient relaps refractori multipl
approv japan treatment relaps refractori r/r b-
expand indic eu includ pediatr ph-r/r
bcma bite bite
phase data present expect
approv eu prevent migrain adult
dose option
combin
 patient
relaps
aimovig approv eu
prevent
migrain adult
antibodi migrain prevent
complet phase studi expect year-end
approv china treatment adult adolesc
year old homozyg famili hypercholesterolemia
phase studi initi subject elev lp
advanc phase heart failur
therapi design
patient sever
asthma without
fda grant breakthrough-therapi design patient sever
asthma without eosinophil phenotyp
expect revenu rang
expect non-gaap ep rang
gaap ep expect rang
adjust tax rate expect rang
revenu increas quarter due
strong double-digit volume-driven growth new recent launch
product product sale grew quarter new
recent launch product includ repatha prolia kyproli xgeva
repatha grew quarter due higher unit
demand repatha approv sale china drive growth
futur prolia best gross product sale grew
quarter due higher unit demand
xgeva sale grew quarter due higher unit
sale xgeva approv use patient multipl myeloma earli
help product take market share
kyproli sale increas quarter due growth
intern sale number new patient increas kyproli
approv food drug administr per week dose
enbrel declin sale face marketplac competit
caus lower price product total revenu neulasta
declin quarter due increas
competit lower sell price neulasta expect face biosimilar
competit come year
non-gaap ep increas due higher total revenu
lower tax rate lower weighted-averag share outstand non-gaap
oper incom decreas non-gaap oper margin
decreas quarter gener free cash
flow quarter
launch kanjinti amgevita europ
import growth driver new product launch like repatha
prolia aimovig offer attract long-term prospect
increas
quarter due
new recent
launch
kanjinti amgevita
europ
new
repatha prolia
non- reconcili
non- reconcili
non- reconcili
incom statement
non-
per share item
product perform develop
valuat consensu perform
revenu growth ttm compar
ep growth ttm compar
net margin increas ttm compar
oper margin ttm compar
ratio revenu margin margin inc margin rate margin turnov averag asset leverag averag equiti year averag averag averag year averag averag averag year averag averag averag growth growth ex sale /sale /net incom ratio profit marginsprofitabilityrevenu growth oper incom growthep growth inc decemb
mrqgross mrqcog mrqoper mrqnet mrqsg mrqr sale amgen inc decemb
invest flow
sale
mrqyoy growth revenu growthoper incom growthep mrq ratio growth yoy oper growth yoy free growth mrqcapex salescap ex salesfre mrqfinanci mrqreturn mrqreturn asset amgen inc decemb
per share item ratio
fiscal per ebitda per ebit per earn per share ep ep free flow per dividend per book valu per tangibl book per month end stock month end stock equiti return asset return invest capit return capit joel greenblatt debt gross margin oper margin net margin total equiti total lt debt total asset dividend pay-out day sale day account day convers inventori cog inventori tax rate net incom net incom discontinued- net net margin prefer dividends- annual itemsquarterli item amgen inc decemb
outstand equival market debt common prefer stock- purchas properti plant sale properti plant purchas sale business- purchas sale issuanc repurchas net issuanc prefer stock- net issuanc net chang capit free inc decemb
price-to-earnings trail current price-to-earnings
averag price-to-earnings price-to-earnings volatil past three year due declin ep
increas stock price expect forward price-to-earnings
incom statement
non-
per share item
product perform develop
valuat consensu perform
breakdown share held share held float held institut hold institut holdersholdersharesd report outvaluefmr vanguard group inc capit research global primecap manag america northern trust geod capit manag top mutual fund holdersholdersharesd report outvaluevanguard total stock market vanguard vanguard/primecap invest compani capit world growth incom spdr etf vanguard institut fund-institut capit incom builder amcap growth fund america competit
developmentsamgen magellan rx manag collabor improv patient chronic difficult-to-treat conditionsdecemb announc collabor magellan rx manag pharmaci benefit manag divis leverag compani capabl resourc identifi clinic gap healthcar system difficult-to-treat diseas base onamgenand magellan extens expertis complex area health specialti popul initi project focu improv patient outcom treatment osteoporosi migrain project markamgen sfirst value-bas collabor pharmaci benefit manag pbm amgen receiv chmp posit opinion expand use blincyto blinatumomab patient minim residu disease-posit b-cell precursor acut lymphoblast leukemianovemb thecommitte medicin product human use chmp theeuropean medicin agenc ema adopt posit opinion expand current indic blincyto blinatumomab monotherapi includ adult patient withphiladelphiachromosom neg posit b-cell precursor acut lymphoblast leukemia first second complet remiss minim residu diseas mrd greater equal applic includ data phase blast studi frontlin relapsed/refractori largest prospect trial mrd-posit ever conduct blincyto bispecif cell engag first biteimmunotherapi receiv regulatori approv global amgen present result highlight long-term safeti efficaci repatha evolocumab longest durat studi inhibitor date aha scientif session announc final report theopen-labelstudi oflong-term evalu ldl-c demonstr long-term treatment repatha evolocumab associ robust consist reduct low-dens lipoprotein cholesterol ldl-c increas overal rate advers event time neutral antibodi addit data theget improvedunderstand oflow-dens lipoprotein dyslipidemia manag gould registri reflect disconnect physician percept lipid-low therapi llt actual use highlight need improv patient awar goal llt need address barrier use medic like repatha amgen provent announc co-develop collabor celiac diseasenovemb andprovent inc clinical-stag biopharmaceut compani focus immune-medi diseas today announc licens co-develop agreement identifi provent novel monoclon antibodi develop treatment gluten-fre diet non-respons celiac diseas nrcd develop effort provent led research previou experi develop amgen inc decemb
incom statement
non-
per share item
product perform develop
valuat consensu perform
higher
compar
roa roi roe
actual vs price-to-earnings ratio ttm price-to-earnings high last yr price-to-earnings last yr beta price sale ttm price book mrq price ttm price free ttm errorerrorerror own dividend yield dividend yield year average dividend year growth rate pay-out ratio ttm sale mrq vs qtr yr sale ttm vs ttm yr sale yr growth rate sale yr growth rate ep mrq vs qtr yr ep ttm vs ttm yr ep yr growth rate ep yr growth rate capit spend yr growth rate lt debt equiti mrq total debt equiti mrq interest coverag ttm gross margin ttm gross margin yr average ebitd margin ttm ebitd yr average oper margin ttm oper margin yr average pre-tax margin ttm pre-tax margin yr average net profit margin ttm net profit margin yr average effect tax rate ttm effect tax rate yr average return asset ttm return asset yr average return invest ttm return invest yr average return equiti ttm return equiti yr average revenue/employe ttm net income/employe ttm receiv turnov ttm inventori turnov ttm asset turnov ttm manag effect effici performancevalu ratio dividend growth rate ratio profit inc decemb
consensu view analyst trend stock
forecast
compar
forward price-to-earnings
compar
annual usdgrowth high day day day estim avgfive-year growth forecast comparisonamgnindustri avg avgprice/earn yield inc decemb
consensu view analyst trend stock
sale growth estim
current qtr
next qtr
averag revenu estim
current qtr
next qtr
estimatescurr analyst estimatethi estim estimatepast ep growthprice/earningsobsoleteobsoleteobsoleteobsoletepeg ratioobsoleteobsoleteobsoleteobsoleteconsensu ep day day day day ep revisionsn/an/an/an/aup last last daysn/an/an/an/adown last dayserrorerrorerrorerrordown last dayscurr surprisescurr growth rate amgen inc decemb
incom statement
non-
per share item
product perform develop
valuat consensu perform
stock price movement volatil quarter surg novemb
stock gave return period averag daili volum share
trade quarter
stock price volatil decemb april later show upward trend
surg novemb
stock given return past rang stock
stock price show huge fluctuat past surg novemb
stock given return past
revenu grew quarter due double-digit growth new recent
launch product includ repatha prolia aimovig recommend hold rate
tp base forward price-to-earnings multipl adjust ep give
upsid potenti stock volatil quarter
crispidea financi inform servic firm focus provid equiti research portfolio manag
person wealth manag brokerag servic inform servic side provid commun
consult research servic host client
crispidea track limit number compani sector strive provid qualiti insight straight
forward analysi object creat long-term wealth moder low risk crispidea leverag
larg number in-hous extern expert oper within industri strong financi oper
strateg background
detail visit www crispidea com contact
